Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was $2.33M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $2.33M.

Context

  • Cost of revenue amounted to 32052.8% of revenue in FY2025, up 32052.8 pp from a year earlier.
  • Cost of revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near $2.33M or moves back toward the trailing-twelve-month quarterly average of $583K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.33M— QoQ
Last fiscal yearDec 2025
$11.54M— YoY
LTMMar 2026
$2.33M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
11.54M USD
Year-over-year change
—

Cost of Revenue vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 7522.6% of revenue for LYEL, versus a peer median of 47.5%.
LYEL Competitors
Cost of Revenue for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$102.11M USD-27.2%-9.9%47.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$77.25M USD-23.8%-4.7%—
EDITEditas Medicine, Inc.LTM Mar 2026$36.44M USD-53.4%—94.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M USD——7522.6%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$866K USD-97.1%——
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
GNLXGenelux CorporationLTM Mar 2026$292K USD+43.1%-16.0%3650.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$66.6K USD———
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$0 USD———
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
Peer median (excluding LYEL) —-27.2%-12.9%47.5%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.65M84.68M130K61K36K
Cost of Revenue000011.54M
Gross Profit10.65M84.68M130K61K(11.5M)
Gross Margin100.0%100.0%100.0%100.0%-31952.8%
Research & Development138.69M159.19M182.95M171.6M158.68M
Selling, General & Admin89.06M117.31M66.98M52.04M45.14M
Operating Expenses225.43M271.74M247.14M358.82M192.27M
Depreciation & Amortization13.62M18.02M20.25M19.63M11.54M
EBITDA(236.6M)(165.1M)(214.38M)(200.64M)(262.91M)
EBITDA Margin-2221.5%-195.0%-164909.2%-328923.0%-730302.8%
Operating Income(214.78M)(187.06M)(247.01M)(358.76M)(203.77M)
Operating Margin-2016.7%-220.9%-190006.2%-588123.0%-566038.9%
Interest Income1.17M7.05M23.45M24.07M13.08M
Interest Expense00000
Other Income / Expenses(35.44M)3.94M12.38M15.76M(70.67M)
Income Before Tax(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Pre-Tax Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
Income Tax Expense00000
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Net Margin-2349.5%-216.2%-180486.2%-562285.2%-762355.6%
EPS (Basic)(1.03)(0.74)(0.93)(1.31)(16.06)
EPS (Diluted)(1.03)(0.74)(0.93)(1.31)(16.06)
Weighted Avg Shares12.14M12.35M12.55M13.07M17.09M
Weighted Avg Shares (Diluted)12.14M12.35M12.55M13.07M17.09M

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.